Critical Care Reviews Newsletter

Welcome to a brief supplemental Critical Care Reviews Newsletter, bringing you the four randomised controlled trials and one observational study which were presented at the Brussels Intensive Care Meeting today and simultaneously published.

Randomised Controlled Trials

• Dequin. Hydrocortisone in Severe Community-Acquired Pneumonia. N Engl J Med 2023;epublished March 21st
• Bouzat. Efficacy and Safety of Early Administration of 4-Factor Prothrombin Complex Concentrate in Patients With Trauma at Risk of Massive TransfusionThe PROCOAG Randomized Clinical Trial. JAMA 2023;epublished March 21st
• Annane. Intravenous ravulizumab in mechanically ventilated patients hospitalised with severe COVID-19: a phase 3, multicentre, open-label, randomised controlled trial. Lancet Respir Med 2023;epublished March 20th
• Reignier. Low versus standard calorie and protein feeding in ventilated adults with shock: a randomised, controlled, multicentre, open-label, parallel-group trial (NUTRIREA-3). Lancet Respir Med 2023;epublished March 20th

Observational Studies

• Goligher. Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19. JAMA 2023;epublished March 21st
  
  • Editorial:  Dahabreh. Toward Personalizing Care. Assessing Heterogeneity of Treatment Effects in Randomized Trials. JAMA 2023;epublished March 21st

I hope you find this newsletter useful.

Until the weekend

Rob